

AWARD NUMBER: W81XWH-06-1-0528

TITLE: Checkpoint Kinase-Dependent Regulation of DNA Repair and Genome Instability in Breast Cancer

PRINCIPAL INVESTIGATOR: Courtney A. Lovejoy

CONTRACTING ORGANIZATION: Vanderbilt University
Nashville, TN 37232

REPORT DATE: June 2009

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 1 June 2009		2. REPORT TYPE Annual Summary		3. DATES COVERED 1 June 2006 – 31 May 2009	
4. TITLE AND SUBTITLE Checkpoint Kinase-Dependent Regulation of DNA Replication and Genome Instability in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0528	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Courtney A. Lovejoy E-Mail: courtney.lovejoy@vanderbilt.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Nashville, TN 37232				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The DNA damage response (DDR) functions as a tumorigenesis barrier. It is activated in precancerous lesions, potentially as a consequence of aberrant DNA replication. The genetic alterations that create this genomic instability are poorly defined. Using a functional genomic screen in human cells we identified seventy-four genes that when silenced by RNAi activate the DDR. Using a series of secondary assays we determined that many have DNA replication-associated genome maintenance activities. In particular, we identified DDB1 as a genome maintenance gene, and further demonstrated that the replication-dependent genome maintenance activity of DDB1 involves the ubiquitin-mediated degradation of the replication protein CDT1. Our RNAi screen also identified CDK2-interacting protein (CINP) as a genome maintenance gene. Further characterization of CINP revealed this protein is a novel regulator of the ATR-mediated DDR pathway. CINP binds ATR through the ATR-interacting protein (ATRIP), and regulates ATR-dependent CHK1 phosphorylation and maintenance of the G2 checkpoint. Approximately seventeen of the seventy-four genome maintenance genes are known or putative tumor suppressors, including six that were identified as being mutated in breast and colorectal cancers by a cancer genome sequencing effort. Our results suggest that loss of these gene functions may promote tumorigenesis by causing genomic instability.					
15. SUBJECT TERMS genome maintenance, DNA damage response, replication					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	29	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusion.....	11
References.....	13
Appendix.....	15

Introduction

Defects in genome maintenance are the underlying cause of many human diseases, most notably cancer (24) (11). DNA damage and replication stress responses are critical regulators of genome integrity. Activation of the DNA damage response (DDR) in pre-cancerous lesions, including those of the breast, is hypothesized to be a response to genetic alterations that promote aberrant cycles of DNA replication resulting in genome instability (5) (7). The genetic alterations underlying this instability are unknown in most cases.

The ataxia-telangiectasia mutated (ATM) and ATM-and Rad3 related (ATR) kinases function at the apex of the DDR signaling pathways to coordinate cell cycle and DNA repair activities (10). Defects in ATM, as well as the ATM/ATR substrates CHK2, TP53, and BRCA1, have been specifically implicated in breast tumorigenesis (4, 6, 15, 16, 20, 22, 25). The importance of DDR pathways in breast tumorigenesis suggests that a broader understanding of how genome integrity is maintained will provide greater knowledge about the etiology of breast cancer.

Interfering with genome maintenance activities causes activation of DDR signaling even in the absence of any exogenous genotoxic agent (1, 3, 13). Since DDR activation can provide a specific assay for genome integrity challenges, especially those associated with replication stress, we designed an RNAi screen using markers of an activated DDR to identify novel regulators of genome maintenance.

Body

The initial task of the proposed research was to define how the DDR maintains genome stability through the regulation of ribonucleotide reductase (RNR). This enzyme catalyzes the rate-limiting step in the formation of dNTPs for DNA synthesis and repair. Aberrations in RNR activity accelerate the mutation rate, and thus promote the genomic instability that is a prerequisite for tumorigenesis (14, 26). RNR also has an important role in the progression and treatment of cancer (17, 28).

As indicated in the statement of work, our initial task was to determine if the activity of RNR is regulated by the DDR kinase ATR. In accordance with the outlined experiments of Task 1, RNR subunits were cloned, epitope tagged, and stably expressed in conditional ATR knockout cell lines. However, the overexpression of RNR was not sufficient to suppress the lethality associated with deletion of ATR from this cell line. Additionally, we attempted to measure dNTP pools using both an enzymatic assay and HPLC. The reproducibility of the enzymatic assay was compromised by contaminants in the cell extracts, and cellular dNTP levels were too low to accurately identify by HPLC any changes that might be occurring with various treatments. We therefore had insufficient evidence to suggest that the ATR-mediated checkpoint pathway has a role in the regulation of RNR activity or dNTP levels. Accordingly, experiments to identify the mammalian inhibitor of RNR, as outlined in part C of Task 1, were suspended.

The aim of Task 2 was to determine if the DDB1-Cul4A ubiquitin ligase complex is required for the regulation of RNR activity. Our initial experiments suggested that DDB1, like RNR, has a role in the maintenance of genome integrity. We discovered that siRNA-mediated silencing of DDB1 results in DDR activation due to the generation of

endogenous DNA damage (19). Additional experiments revealed that the DNA damage and DDR activation observed after DDB1 silencing was independent of its function in nucleotide excision repair. A similar phenotype was observed following silencing of Cul4A, suggesting that the ubiquitin ligase activity of the DDB1-Cul4A complex is important for genome maintenance (19).

The genome maintenance function of DDB1-Cul4A was further characterized, and our experiments revealed that one of the relevant substrates of this ubiquitin ligase activity is Cdt1 (19). Cdt1 is a component of the pre-replication complex that assembles in G1 phase of the cell cycle in preparation for origin firing and DNA replication during S phase. The strict regulation of this protein is necessary to ensure that replication origins fire only once during S phase. The re-firing of replication origins during a single S phase is referred to as re-replication (3). Silencing of DDB1 or Cul4A perturbs Cdt1 regulation and results in increased cellular levels of Cdt1 protein, allowing re-replication that results in DNA damage and DDR activation. As also outlined in Task 2, fragile site stability was monitored after silencing of DDB1. While there was an increase in the number of breaks per cell following DDB1 silencing, there was no enhancement observed at common fragile sites (19). The breaks instead appeared to occur throughout the genome, suggesting that re-replication causes double strand DNA breaks through a mechanism distinct from that which occurs following the stalling of replication forks.

Our work identified DDB1 as a genome maintenance gene. The genome maintenance activity of this gene product was characterized, in part, as being required for the regulation of Cdt1 (19). While the genome maintenance activities of DDB1 are replication-dependent, we have no evidence to suggest that the regulation of RNR

activity contributes to the genome maintenance functions of DDB1. Furthermore, the experiments performed to address Task 1, in combination with published data from other groups, suggests the mammalian RNR may not be regulated in a manner similar to that observed in model organisms, where ubiquitin-mediated degradation of an RNR inhibitor is required for RNR activation (8, 12, 18). With insufficient evidence for a connection between DDB1-Cul4A and RNR activation, we chose to suspend the experiments outlined in the final two aims of Task 2. Our efforts were instead re-directed toward a broader understanding the cellular processes that contribute to maintaining genome integrity.

We developed a functional genomics screen in human cells to identify genome maintenance activities. This RNAi screen used markers of an activated DDR to identify genetic disruptions that challenge genome integrity. The RNAi library screened was selected from a genome-wide shRNA library, and specifically enriched for genes with potential nuclear regulatory activities. In total, we analyzed 6,386 RNAi molecules targeting 2,287 genes. Our primary screen resulted in the identification of 130 candidate genome maintenance genes.

To validate these candidates, an additional marker of DDR activation was examined using a different source of RNAi in a cell type distinct from that used for the primary screen. Of the 130 candidate genes, 74 were validated as genome maintenance genes. The DDR activation resulting from RNAi inhibition of these 74 genes is unlikely to be off-target because at least three independent RNAi molecules targeting the same gene results in DDR activation. Furthermore, validation with two cell types and two

markers of DDR activation indicates these genes encode general regulators of genome maintenance rather than cell-type specific activities.

Secondary assays were developed to identify those genes with replication-dependent genome maintenance activities since replication stress is thought to promote genetic instability in pre-cancerous lesions and facilitate tumorigenesis (9). These assays identified gene products that may have replication-dependent genome maintenance activities, as well as gene products that may have novel roles in replication processes.

One gene product that displayed DDR activation and sensitivity to replication stress was Cdk2-interacting protein (CINP). This gene product was of particular interest because our lab previously found it to associate with the ATR-interacting protein ATRIP in a yeast two-hybrid assay. The genome maintenance activity of CINP and its potential interaction with the DDR protein ATRIP prompted us to characterize this gene product further. Subsequent analyses confirmed that CINP interacts with the ATR-ATRIP complex, and that the ATRIP coiled-coil domain mediates this interaction. Silencing of CINP disrupts phosphorylation of the ATR-ATRIP substrates CHK1 and SMC1, and also disrupts the maintenance of the G2 checkpoint following irradiation.

Manuscripts for both the RNAi screen and the characterization of CINP as a novel regulator of ATR signaling are in preparation.

Key Research Accomplishments

- Completion of a functional genomic screen in human cells
- Identification and validation of 74 genes with genome maintenance activities
- Characterization of genome maintenance genes with replication-dependent genome maintenance activities
- Identification of a the replication-dependent genome maintenance activity of DDB1 as degradation of the replication licensing factor Cdt1
- Identification of the genome maintenance activity of CINP as a novel regulator of ATR checkpoint signaling

Reportable Outcomes

1. Poster presentation describing the genome maintenance activity of DDB1
 - a. Title: DDB1 maintains genome integrity through regulation of Cdt1
 - b. Authors: Courtney A. Lovejoy, Kimberli Lock, Ashwini Yenamandra, and David Cortez
 - c. Meeting: DNA replication and genome integrity meeting
 - i. San Diego, CA; August 2006
2. Oral presentation of the RNAi screen for genome maintenance genes
 - a. Title: A functional genomic screen identifies genes with novel roles in the maintenance of genome integrity
 - b. Authors: Courtney A. Lovejoy, Xin Xu, Gloria G. Glick, Carol E. Bansbach, Laura C. Titus, David Cortez
 - c. Meeting: Maintenance of Genome Stability Conference, sponsored by Abcam
 - i. Puerto Vallarta, Mexico; March 2008

3. Poster presentation of the described RNAi screen
 - a. Title: A functional genomic screen identifies genes with novel roles in the maintenance of genome integrity
 - b. Authors: Courtney A. Lovejoy, Xin Xu, Laura C. Titus, Carol E. Bansbach, Gloria G. Glick, David Cortez
 - c. Meeting: Department of Defense Era of Hope Meeting
 - i. Baltimore, MD; June 2008

4. Poster presentation of the described RNAi screen
 - a. Title: A functional genomic screen identifies genes with novel roles in the maintenance of genome integrity
 - b. Authors: Courtney A. Lovejoy, Xin Xu, Laura C. Titus, Carol E. Bansbach, Gloria G. Glick, David Cortez
 - c. Meeting: DNA replication and genome integrity
 - i. San Diego, CA; July 2008

5. Publication of the manuscript characterizing a genome maintenance activity of DDB1
 - a. Title: An RNAi screen for genome maintenance activities identifies CINP as a novel regulator of ATR checkpoint signaling
 - b. Authors: Courtney A. Lovejoy, Xin Xu, Gloria G. Glick, Carol E. Bansbach, Laura C. Titus, David Cortez
 - c. Published: 2006 *Mol Cell Biol.* 26:7977-90

6. Publication of a review on PIKK family kinases
 - a. Title: Common mechanisms of PIKK regulation
 - b. Authors: Courtney A. Lovejoy and David Cortez
 - c. Published: 2009 *DNA Repair (Amst)* May 20

7. Publication characterizing CINP as a novel DNA damage response protein
 - a. Title: CINP regulates ATR checkpoint signaling
 - b. Authors: Courtney A. Lovejoy, Xin Xu, Gloria G. Glick, Biana M. Sirbu, Runxiang Zhao, and David Cortez
 - c. Manuscript in preparation for *PNAS*

8. Publication describing the RNAi screen (in combination with the characterization of a gene identified in the screen)
 - a. Title: The annealing helicase SMARCAL1 maintains genome integrity at replication forks
 - b. Authors: Carol E. Bansbach*, Courtney A. Lovejoy*, Runxiang Zhao, Gloria G. Glick, David A. Cappel, Fei Ye, Laura Titus, Yu Shyr, and David Cortez
 - i. *co-first authors
 - c. Manuscript is being revised after review at *Nat Cell Biol.*

9. Successful defense of dissertation research
 - a. Title: Replication dependent mechanisms of genome maintenance
 - b. Vanderbilt University Medical Center, March 2009

Conclusions

Our data indicate DDB1 is required for maintaining genome stability in human cells. Silencing of DDB1 expression results in an accumulation of DNA damage, including double strand breaks, and the activation of cell cycle checkpoints. DDB1 protects the integrity of the genome through its role as part of an E3 ubiquitin ligase complex containing Cul4A. One target of this complex that must be degraded to preserve genome integrity is the replication licensing factor Cdt1. Multiple levels of Cdt1 regulation exist in human cells. Our data indicate these mechanisms possess unique and necessary roles in the regulation of Cdt1, to properly restrain this protein and prevent the adverse cellular consequences associated with its misregulation (19).

We demonstrate that re-replication does occur in DDB1-depleted cells despite the presence of other mechanisms that presumably continue to operate to suppress the re-firing of replication origins. Previous data from human systems has suggested that the

DDB1-Cul4 and SCF^{Skp2} mechanisms of Cdt1 destruction are redundant in the absence of exogenous DNA damage (21). However, the disruption of a single mode of Cdt1 regulation in other organisms was shown to be sufficient to have adverse effects (2) (27). The stabilization of Cdt1 and the presence of re-replication that we observed after DDB1 depletion argue against redundant roles for DDB1-Cul4A and SCF^{Skp2} in the destruction of Cdt1 in human cells. We propose that the DDB1-dependent degradation of Cdt1 is particularly important because the loss of DDB1 creates a situation in which at least one other mechanism of Cdt1 regulation is also inactivated. Depletion of DDB1 generates DNA damage that activates cell cycle checkpoints, which in turn function to inactivate CDK complexes (23). Since the SCF^{Skp2}-mediated destruction of Cdt1 requires a CDK-mediated phosphorylation event, this pathway is inhibited by the presence of active checkpoints. Therefore, disruption of DDB1 eliminates both ubiquitin-dependent mechanisms of Cdt1 regulation, which will likely result in further re-replication, greater DNA damage, and amplification of genome instability.

In addition to identifying DDB1 as a genome maintenance gene and characterizing one of its genome maintenance functions, we have also identified and characterized a genome maintenance function of CDK2-interacting protein (CINP). We demonstrated that CINP is a novel checkpoint protein required for ATR-mediated checkpoint signaling. CINP forms a complex with ATR-ATRIP through the ATRIP coiled-coil domain, is required for efficient phosphorylation of CHK1 after DNA damage, and is required for maintenance of the G2 checkpoint.

CINP is one of 74 genome maintenance genes identified through our functional genomic screen. The genes identified in this RNAi screen illustrate the diversity of the

cellular processes involved in maintaining genome integrity and emphasize our incomplete understanding of this critical cellular activity. Mutations or disruptions in the activity of many of these genes contribute to tumorigenesis. Further characterization of their genome maintenance activities will increase our understanding of the causes of genome instability in breast cancer cells. To begin this process, we have defined those genes with replication-dependent genome maintenance activities, providing the first evidence of a role in replication-dependent processes for several of these gene products. The identification of genes with replication-dependent genome maintenance activities provides new insights into the mechanisms of replication control, and also identifies candidates for genetic alterations that cause DDR activation in pre-cancerous lesions, including those of the breast.

References

1. Aguilera, A., and B. Gomez-Gonzalez. 2008. Genome instability: a mechanistic view of its causes and consequences. *Nat Rev Genet* 9:204-17.
2. Arias, E. E., and J. C. Walter. 2006. PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication. *Nat Cell Biol* 8:84-90.
3. Arias, E. E., and J. C. Walter. 2007. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. *Genes Dev* 21:497-518.
4. Athma, P., R. Rappaport, and M. Swift. 1996. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. *Cancer Genet Cytogenet* 92:130-4.
5. Bartkova, J., Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas, and J. Bartek. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 434:864-70.
6. Davidoff, A. M., P. A. Humphrey, J. D. Iglehart, and J. R. Marks. 1991. Genetic basis for p53 overexpression in human breast cancer. *Proc Natl Acad Sci U S A* 88:5006-10.
7. Gorgoulis, V. G., L. V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R. A. Dittullo, Jr., N. G. Kastrinakis, B. Levy, D. Kletsas,

- A. Yoneta, M. Herlyn, C. Kittas, and T. D. Halazonetis. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* 434:907-13.
8. Hakansson, P., A. Hofer, and L. Thelander. 2006. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. *J Biol Chem* 281:7834-41.
 9. Halazonetis, T. D., V. G. Gorgoulis, and J. Bartek. 2008. An oncogene-induced DNA damage model for cancer development. *Science* 319:1352-5.
 10. Harper, J. W., and S. J. Elledge. 2007. The DNA damage response: ten years after. *Mol Cell* 28:739-45.
 11. Hoeijmakers, J. H. 2001. Genome maintenance mechanisms for preventing cancer. *Nature* 411:366-74.
 12. Holmberg, C., O. Fleck, H. A. Hansen, C. Liu, R. Slaaby, A. M. Carr, and O. Nielsen. 2005. Ddb1 controls genome stability and meiosis in fission yeast. *Genes Dev* 19:853-62.
 13. Hook, S. S., J. J. Lin, and A. Dutta. 2007. Mechanisms to control rereplication and implications for cancer. *Curr Opin Cell Biol* 19:663-71.
 14. Ingraham, H. A., L. Dickey, and M. Goulian. 1986. DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. *Biochemistry* 25:3225-30.
 15. Inskip, H. M., L. J. Kinlen, A. M. Taylor, C. G. Woods, and C. F. Arlett. 1999. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. *Br J Cancer* 79:1304-7.
 16. Janin, N., N. Andrieu, K. Ossian, A. Lauge, M. F. Croquette, C. Griscelli, M. Debre, B. Bressac-de-Paillerets, A. Aurias, and D. Stoppa-Lyonnet. 1999. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. *Br J Cancer* 80:1042-5.
 17. Kuo, M. L., H. S. Hwang, P. R. Sosnay, K. A. Kunugi, and T. J. Kinsella. 2003. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. *Cancer J* 9:277-85.
 18. Liu, C., K. A. Powell, K. Mundt, L. Wu, A. M. Carr, and T. Caspari. 2003. Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. *Genes Dev* 17:1130-40.
 19. Lovejoy, C. A., K. Lock, A. Yenamandra, and D. Cortez. 2006. DDB1 maintains genome integrity through regulation of Cdt1. *Mol Cell Biol* 26:7977-90.
 20. Meijers-Heijboer, H., A. van den Ouweland, J. Klijn, M. Wasielewski, A. de Snoo, R. Oldenburg, A. Hollestelle, M. Houben, E. Crepin, M. van Veghel-Plandsoen, F. Elstrodt, C. van Duijn, C. Bartels, C. Meijers, M. Schutte, L. McGuffog, D. Thompson, D. Easton, N. Sodha, S. Seal, R. Barfoot, J. Mangion, J. Chang-Claude, D. Eccles, R. Eeles, D. G. Evans, R. Houlston, V. Murday, S. Narod, T. Peretz, J. Peto, C. Phelan, H. X. Zhang, C. Szabo, P. Devilee, D. Goldgar, P. A. Futreal, K. L. Nathanson, B. Weber, N. Rahman, and M. R. Stratton. 2002. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nat Genet* 31:55-9.
 21. Nishitani, H., N. Sugimoto, V. Roukos, Y. Nakanishi, M. Saijo, C. Obuse, T. Tsurimoto, K. I. Nakayama, K. Nakayama, M. Fujita, Z. Lygerou, and T.

- Nishimoto. 2006. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. *Embo J* 25:1126-36.
22. Pharoah, P. D., N. E. Day, and C. Caldas. 1999. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. *Br J Cancer* 80:1968-73.
 23. Sancar, A., L. A. Lindsey-Boltz, K. Unsal-Kacmaz, and S. Linn. 2004. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem* 73:39-85.
 24. Schar, P. 2001. Spontaneous DNA damage, genome instability, and cancer--when DNA replication escapes control. *Cell* 104:329-32.
 25. Swift, M., P. J. Reitnauer, D. Morrell, and C. L. Chase. 1987. Breast and other cancers in families with ataxia-telangiectasia. *N Engl J Med* 316:1289-94.
 26. Yoshioka, A., S. Tanaka, O. Hiraoka, Y. Koyama, Y. Hirota, D. Ayusawa, T. Seno, C. Garrett, and Y. Wataya. 1987. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. *J Biol Chem* 262:8235-41.
 27. Zhong, W., H. Feng, F. E. Santiago, and E. T. Kipreos. 2003. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. *Nature* 423:885-9.
 28. Zhou, B. S., P. Tsai, R. Ker, J. Tsai, R. Ho, J. Yu, J. Shih, and Y. Yen. 1998. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. *Clin Exp Metastasis* 16:43-9.

Appendix

Reprint of Lovejoy et al. (2006). DDB1 maintains genome integrity through regulation of Cdt1. *Mol Cell Biol* 26:7977-90.

DDB1 Maintains Genome Integrity through Regulation of Cdt1^{∇†}

Courtney A. Lovejoy,¹ Kimberli Lock,² Ashwini Yenamandra,² and David Cortez^{1*}

*Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232,¹
and Genetics Associates, Inc., Nashville, Tennessee 37203²*

Received 8 May 2006/Returned for modification 3 July 2006/Accepted 22 August 2006

DDB1, a component of a Cul4A ubiquitin ligase complex, promotes nucleotide excision repair (NER) and regulates DNA replication. We have investigated the role of human DDB1 in maintaining genome stability. DDB1-depleted cells accumulate DNA double-strand breaks in widely dispersed regions throughout the genome and have activated ATM and ATR cell cycle checkpoints. Depletion of Cul4A yields similar phenotypes, indicating that an E3 ligase function of DDB1 is important for genome maintenance. In contrast, depletion of DDB2, XPA, or XPC does not cause activation of DNA damage checkpoints, indicating that defects in NER are not involved. One substrate of DDB1-Cul4A that is crucial for preventing genome instability is Cdt1. DDB1-depleted cells exhibit increased levels of Cdt1 protein and rereplication, despite containing other Cdt1 regulatory mechanisms. The rereplication, accumulation of DNA damage, and activation of checkpoint responses in DDB1-depleted cells require entry into S phase and are partially, but not completely, suppressed by codepletion of Cdt1. Therefore, DDB1 prevents DNA lesions from accumulating in replicating human cells, in part by regulating Cdt1 degradation.

Damaged DNA binding protein 1 (DDB1) was identified as part of a heterodimer that tightly associates with DNA following UV damage (14). This heterodimer of DDB1 and damaged DNA binding protein 2 (DDB2) was subsequently discovered to have a role in nucleotide excision repair (NER). There are two subpathways of NER: global genomic repair (GGR) removes lesions throughout the genome, while transcription-coupled repair (TCR) removes lesions more readily from the transcribed strand of active genes. Defects in the chromatin binding property of the DDB1-DDB2 complex reduce the GGR capacity of cells by approximately 50% (28, 61). Genetic defects in NER give rise to the autosomal recessive disorder xeroderma pigmentosum (XP), which is characterized by extreme sun sensitivity, premature aging, and an increased incidence of skin cancer. Eight complementation groups have been defined for XP, with seven resulting from unique defects in proteins required for NER (15, 58). Mutations in *DDB2* are classified as XP complementation group E (XP-E) (30, 47).

Further studies revealed that it is not simply a heterodimer of DDB1-DDB2 that binds DNA and stimulates GGR following UV damage but a larger complex of proteins that possess an active ubiquitin ligase activity. In addition to DDB1 and DDB2, the soluble complex contains the E3 protein cullin 4A (Cul4A), the Roc1 RING subunit that is required for Cul4A activity, and a cullin regulatory complex termed the COP9 signalosome (CSN) (21). Following chromatin association, this active ubiquitin ligase targets XPC, a damage sensor for the GGR pathway. Ubiquitination of XPC does not result in proteasomal degradation but instead enhances the ability of XPC

to remain associated with chromatin (56). Another target of this chromatin-bound complex is the DDB2 protein itself. DDB2 is rapidly degraded after UV damage and is ubiquitinated *in vitro* by DDB1-Cul4A (13, 39, 44). The ubiquitination of DDB2 reduces the DNA binding ability of DDB1-Cul4A and is necessary for efficient repair of UV-induced lesions (56). Recently, the monoubiquitination of histone H2A at sites of UV-induced damage was also shown to require DDB1-Cul4 (29). This modification may have an important role in facilitating GGR as well. Interestingly, a complex identical to that of DDB1-DDB2-Cul4A-Roc1-CSN was identified in which DDB2 is replaced by CSA, a protein that is defective in patients with Cockayne syndrome. Unlike the DDB2 complex, the CSA complex has a role in TCR (21).

DDB1 has important roles outside of NER as an adaptor molecule for the Cul4A ubiquitin ligase complex. Studies of *Schizosaccharomyces pombe* revealed that DDB1 and Pcu4, the Cul4 homologue in yeast, promote the ubiquitin-mediated degradation of an inhibitor of ribonucleotide reductase (RNR) (8, 25, 35). This inhibitor prevents the association of the two RNR subunits, an event that is necessary for the catalytic activity that converts nucleoside triphosphates to deoxynucleoside triphosphates for DNA synthesis and repair (12, 35). Additionally, the DDB1-Cul4A complex promotes Cdt1 degradation in human cells after ionizing radiation (IR) and UV damage and also has a role in the replication-dependent destruction of Cdt1 (2, 24, 26, 27, 45, 52). Cdt1 is a component of the prereplication complex, which assembles in an ordered fashion during G₁ to license origins of replication for initiation of DNA synthesis. Regulation of Cdt1 is a critical means by which human cells prevent rereplication. Rereplication occurs when a replication origin fires more than once in a single cell division cycle (7, 17). This protein is targeted for proteasome-mediated degradation by two ubiquitin ligase complexes, SCF^{Skp2} and DDB1-Cul4A, and is also functionally inhibited by the binding of geminin (2, 24, 26, 34, 36, 45, 59, 71). These multiple levels of Cdt1 regulation emphasize the importance of restraining rereplication

* Corresponding author. Mailing address: Vanderbilt University, Department of Biochemistry, 613 Light Hall, Nashville, TN 37232. Phone: (615) 322-8547. Fax: (615) 343-0704. E-mail: David.Cortez@vanderbilt.edu.

† Supplemental material for this article may be found at <http://mcb.asm.org/>.

∇ Published ahead of print on 28 August 2006.

and highlight the need to understand how these distinct processes cooperate to maintain the integrity of the genome.

In addition to DDB1-DDB2, several other protein complexes are recruited to and activated by UV radiation-induced lesions. Principal among these UV response proteins is ATR. ATR- and Rad3-related kinase (ATR) is a member of the phosphatidylinositol 3-kinase-related kinase family, which also includes the damage response protein ataxia-telangiectasia mutated (ATM). These proteins are situated at the apex of the DNA damage response pathways and function to protect the stability of the genome by initiating signal transduction cascades that result in the inhibition of cell cycle progression and the coordination of DNA repair (1, 50). While ATM responds primarily to the formation of DNA double-strand breaks, ATR is activated by a wide variety of lesions and stresses, including UV radiation, DNA alkylation, and replication inhibitors, as well as double-strand breaks. Downstream targets of these active kinases that are important in mediating cell cycle arrest and facilitating DNA repair include the checkpoint kinases Chk1 and Chk2, p53, and the histone variant H2AX (4, 11, 22, 37, 40, 46, 63, 69). Since ATR is responsible for initiating the checkpoint response to UV radiation, and both DDB1 and ATR are recruited to UV lesions, we examined whether DDB1 functions in the ATR-mediated DNA damage response to this genotoxic stress. While depletion of DDB1 did not impair ATR-dependent responses to UV, surprisingly, we found that depletion of DDB1 caused DNA double-strand breaks and activation of checkpoint responses. This phenotype is due, in part, to the misregulation of DNA replication.

MATERIALS AND METHODS

Cell culture. U2OS and HeLa cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 7.5% fetal bovine serum at 37°C in 5% CO₂. The RPE-hTERT cell line was maintained in Dulbecco's modified Eagle's-F-12 medium supplemented with 10% fetal bovine serum and 0.2% sodium bicarbonate at 37°C in 5% CO₂.

DNA constructs and transfections. The DDB1 construct resistant to degradation by small interfering RNA (siRNA)-mediated silencing was created using site-directed mutagenesis. The following primer and its complement were used to introduce selected wobble base pair mutations: 5'-GGAGAGCAAGGATCTACTCTTTATCTTGACAGC-3'. Calcium phosphate transfections of the Phoenix amphitropic packaging cell line were performed to produce retroviruses. Following infection of U2OS cells with the viral medium, stable cell lines were selected using puromycin. C-terminal hemagglutinin (HA)-tagged Cdt1 expression constructs were generated by PCR in the pLPCX vector. Mutagenesis was performed using the following primers: 5'-TATGAAGCTTATGGAGGCTCGCCGCTACCGACGACGCTGCGCGCCGCCG-3' and 5'-CAAGCTGGCCGTCCGGGCCCCAGC-3'.

siRNA. All siRNA oligonucleotides were purchased from Dharmacon, Inc. The siRNA duplexes were as follows: control siRNA sense strand, 5'-AUGAACGUGAAUUGCUCAAdTdT; DDB1 siRNA sense strand, 5'-GCAAGGACCUGCUGUUUAUUU; Cul4A siRNA sense strand, 5'-GAACCAUAUUUAUAGUGAAU; DDB2 siRNA sense strand, 5'-GAUAUCAUGCUCUGGAAUUAUU; XPC siRNA sense strand, 5'-GCAAUUGGCUUCAUGGAAU; XPA siRNA sense strand, 5'-GGAGACGAUUGUUAUCAAAU; Cdt1 siRNA sense strand, 5'-GCGCAAUUGGCGCAGAUUUU. The Skp2 depletions were achieved using a SMARTpool. Transfections were performed with 200 nM of siRNA using Oligofectamine reagent according to the manufacturer's instructions (Invitrogen).

Cell lysis. Cells were lysed in Igepal lysis buffer (20 mM Tris, pH 7.5, 0.1 M NaCl, 1 mM EDTA, 0.5% Igepal CA 630, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 mM NaF, 20 mM µ-glycerolphosphate, 1 mM sodium vanadate, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonate).

Antibodies. The DDB1 and bromodeoxyuridine (BrdU) antibodies were obtained from BD Biosciences. The ATM and XPC antibodies were purchased from Novus Biologicals. The replication protein A (RPA) p34 (9H8) and XPA

antibodies were purchased from Neomarkers. The anti-p45 Skp2 and anti-HA.11 antibodies were obtained from Zymed and Covance, respectively. The Chk1 (G-4), p53 (DO-1), DDB2 (H-127), and Cdt1 (H-300) antibodies were purchased from Santa Cruz Biotechnology. The Mre11 (12D7) and p21 (EA10) antibodies were obtained from GeneTex, Inc., and Calbiochem, respectively. The Chk2 and ATRIP antibodies were described previously (16, 40). The phosphopeptide-specific antibody to pS1981 of ATM was purchased from Rockland, Inc. The phosphopeptide-specific antibodies to pT68 of Chk2, pS345 of Chk1, and pS15 of p53 were obtained from Cell Signaling Technology. The Cul4A antibody was a gift from Yue Xiong.

Immunofluorescence. For γH2AX and Mre11 immunostaining, cells grown on glass coverslips were fixed and permeabilized with 100% methanol at -20°C for 15 min. After being rinsed twice with phosphate-buffered saline (PBS), cells were incubated in 100% acetone at -20°C for 30 seconds. The cells were then air dried for 1 min, rinsed six times with PBS, and blocked for 15 min at room temperature with 5% bovine serum albumin (BSA) in PBS. Primary antibodies recognizing γH2AX or Mre11 were diluted in 1% BSA-PBS and incubated on cells for 20 min at 37°C with 5% CO₂. After being washed three times with PBS, cells were incubated in secondary antibodies, fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit immunoglobulin G or rhodamine red-X-conjugated donkey anti-mouse immunoglobulin G (Jackson ImmunoResearch Laboratories, Inc.), diluted in 1% BSA-PBS for 20 min at 37°C with 5% CO₂. Cells were washed and counterstained with 4',6'-diamidino-2-phenylindole (DAPI). For RPA34 immunostaining, cells were fixed with 3% paraformaldehyde at room temperature for 10 min and permeabilized with 0.5% Triton X-100 for 10 min on ice. After being blocked at room temperature for 15 min with 5% BSA-PBS, the RPA34 antibody was diluted in 1% BSA-PBS and incubated on cells for 20 min at 37°C with 5% CO₂. Following three washes with PBS, cells were incubated in FITC-conjugated goat anti-mouse secondary antibody, diluted in 1% BSA-PBS, for 20 min at 37°C with 5% CO₂. The cells were washed and counterstained with DAPI. All images were obtained with a Zeiss Axioplan microscope equipped with a Zeiss camera and software.

Fragile site analysis. Fragile sites were induced by treatment of U2OS cells with 0.1 µM aphidicolin for 24 h. Metaphase cells were enriched by treating with Demecolcine solution (Sigma) for 1 h at 37°C. Cells were then incubated in a hypotonic solution (3:1, 0.566% KCl-0.8% sodium citrate) for 15 min at 37°C, fixed by multiple washes with Carnoy fixative (3:1 methanol-acetic acid), and dropped onto slides. Slides were baked at 90°C for 30 min and stained with Giemsa stain. Metaphase spreads were scored for chromosomal gaps and breaks, and common fragile sites were identified based on the idiogram in the work of Richards (48).

RESULTS

Depletion of DDB1 activates cell cycle checkpoints. Both DDB1 and ATR are activated by UV radiation and are recruited to sites of UV-induced DNA damage. In *S. pombe* both these proteins are required for the proteolysis of the replication inhibitor Spd1. The damage inducibility of DDB1, along with its functional relationship to the ATR homologue Mec1 in yeast, led us to test whether DDB1 has a role in the UV response initiated by ATR in human cells. We did not observe any defects in ATR activation in response to DNA damage in DDB1-depleted cells (data not shown). However, during the course of testing this hypothesis we examined the cell cycle distribution of DDB1-depleted cells to ensure that depletion of DDB1 was not having an adverse effect on cell cycle progression. Surprisingly, we found a striking change in the cell cycle distribution of undamaged, DDB1-depleted cells (Fig. 1A). This population shows a considerable increase in cells with 4n DNA content compared to that observed following treatment with a control siRNA. To determine if this accumulation is occurring in G₂ or mitosis, cells were stained with an antibody to phosphorylated histone H3 on serine 10. This phosphorylation event occurs during chromosome condensation and is routinely used as a marker of mitotic cells (23). DDB1 depletion does not increase the percentage of mitotic cells relative to




FIG. 1. Depletion of DDB1 activates cell cycle checkpoints. (A) The cell cycle distribution of HeLa cells transfected with control or DDB1 siRNA oligonucleotides was analyzed by flow cytometry detection of DNA content following propidium iodide staining 3 days after transfection. The percentage of mitotic cells in each population was determined by immunostaining with a phosphopeptide-specific antibody to histone H3 S10. (B) HeLa cells transfected with DDB1 or control siRNA oligonucleotides were processed for flow cytometry 4 days after transfection. Where indicated, the cells were cotransfected with ATM- or ATR-specific siRNA or treated with 8 mM caffeine for 24 h prior to analysis. The depletion efficiency of the ATR and ATM siRNA was monitored by immunoblot analysis. (C to E) Checkpoint signaling was examined in HeLa (C), U2OS (D), and RPE-hTERT (E) cells 3 days after transfection with control or DDB1 siRNA oligonucleotides. Cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted with the indicated antibodies. (F and G) U2OS cells were infected with retroviruses encoding an empty vector or an siRNA-immune Flag-DDB1 cDNA (DDB1*). Following selection the cells were transfected with control or DDB1 siRNA oligonucleotides. Checkpoint signaling was examined 3 days after transfection by immunoblotting with the indicated antibodies (F) or monitoring DNA content by flow cytometry of propidium iodide-stained cells (G).

that observed in control cells (Fig. 1A). In fact, there was a significant decrease in the percentage of mitotic cells in the DDB1-depleted population. Similar results were obtained with two independent DDB1 siRNA oligonucleotides in both U2OS

and HeLa cell lines (data not shown). This observation suggests that depletion of DDB1 causes a cell cycle arrest in G₂.

An arrest in G₂ may indicate that cell cycle progression is halted due to the activation of a cell cycle checkpoint. Treat-

ment with caffeine abrogates the G₂/M checkpoint (32, 51); therefore, if the G₂ arrest in DDB1-depleted cells results from checkpoint activation, the addition of caffeine should overcome this accumulation. Treatment with caffeine for 24 h does reverse the G₂ accumulation of DDB1-depleted cells but also induces apoptosis (as measured by cells with <2n DNA content [Fig. 1B]). Since caffeine has numerous cellular effects, we also directly inhibited two of the checkpoint proteins that initiate the DNA damage response signaling cascade, ATR and ATM. Codepletion of DDB1 with ATR also suppresses the G₂ accumulation that is observed following DDB1 depletion (Fig. 1B). Interestingly, codepletion of DDB1 with ATM cannot prevent the accumulation of cells in G₂ (Fig. 1B). The sensitivity of the 4n accumulation to treatment with caffeine and ATR siRNA provides further evidence that the arrest is in G₂ and that it is dependent on the activation of cell cycle checkpoints.

To determine which checkpoint pathways are induced after DDB1 depletion, we immunoblotted cells with phosphopeptide-specific antibodies that detect activated checkpoint proteins. Immunoblotting of HeLa extracts revealed that ATM S1981, Chk2 T68, and Chk1 S345 are all phosphorylated after depletion of DDB1 (Fig. 1C). A similar observation was made in U2OS cells, where p53 S15 is phosphorylated and p21 is induced specifically after DDB1 depletion (Fig. 1D). To confirm that these results are not limited to transformed cells, the experiment was repeated in an untransformed, telomerase-immortalized epithelial cell line (RPE-hTERT). The results again show p53 S15 phosphorylation and p21 induction specifically after DDB1 depletion (Fig. 1E). These data indicate that depletion of DDB1 causes activation of both ATM- and ATR-dependent cell cycle checkpoints, since Chk2 T68 is predominantly an ATM phosphorylation site and Chk1 S345 is an ATR phosphorylation site (9, 37, 40, 72). Even though both ATM and ATR signaling pathways are activated in the absence of DDB1, ATR siRNA but not ATM siRNA relieved the G₂ checkpoint despite efficient depletion of both proteins (Fig. 1B). The dependency of the G₂ arrest on ATR, but not ATM, may be explained by the role that each of these proteins plays in the G₂/M checkpoint. While ATM is important for initiation of the G₂/M checkpoint response, maintenance of the cell cycle arrest largely relies on the activity of ATR (10).

To confirm that activation of cell cycle checkpoints is due specifically to the depletion of DDB1, we created a DDB1 construct using site-directed mutagenesis of wobble base pairs that is resistant to RNA inhibition by one of the siRNA oligonucleotides. U2OS cell lines were generated that stably express an empty vector or a Flag-tagged siRNA-immune DDB1 mRNA (DDB1*). Depletion of DDB1 from the cell line stably expressing an empty vector results in phosphorylation of Chk2 T68 and p53 S15, as well as p21 induction (Fig. 1F). However, depletion of DDB1 from U2OS cells expressing the siRNA-resistant DDB1 mRNA produces significantly less checkpoint protein phosphorylation and p21 induction (Fig. 1F). The slight amount of residual checkpoint signaling observed in some experiments is likely due to variability in the expression of the DDB1* cDNA in the polyclonal population. Analysis of cell cycle profiles by flow cytometry also revealed that expression of the siRNA-resistant DDB1 mRNA can suppress the G₂ accumulation of cells that is observed after DDB1 depletion

(Fig. 1G). The findings that checkpoint activation and cell cycle arrest can be complemented by expression of an siRNA-resistant DDB1 construct confirm that the observed phenotype is due specifically to depletion of DDB1.

Depletion of DDB1 results in γ H2AX, Mre11, and RPA focus formation. The phosphorylation of Chk2 T68 and Chk1 S345 indicates that both the ATM and ATR damage response pathways are activated. In principle, activation of these kinases could be due to the elimination of a negative regulatory mechanism or the presence of genotoxic stress. To differentiate between these hypotheses, we examined whether phosphorylation of H2AX by checkpoint kinases is restricted to foci or distributed diffusely throughout the genome. If the depletion of DDB1 relieves an inhibitory mechanism restraining the activity of ATM or ATR, then these kinases will be generally active without the presence of DNA damage and H2AX phosphorylation is expected to occur throughout the chromatin. A similar phenomenon is observed when the ATR-activating fragment of TopBP1 is overexpressed in cells (31). Under these circumstances ATR is activated and H2AX is phosphorylated, but the phosphorylation is pan-nuclear rather than occurring in distinct foci because there is no actual DNA damage created by overexpression of the TopBP1 fragment (D. Cortez, unpublished data). In contrast, if DDB1 depletion causes the accumulation of DNA damage, then phosphorylated H2AX should be restricted to discrete intranuclear foci (49). We monitored phosphorylated H2AX (γ H2AX) in U2OS cells by indirect immunofluorescence using a phosphopeptide-specific antibody to Ser-139. In cells treated with control siRNA there is little γ H2AX focus formation (Fig. 2A and 2B). Approximately 5% of the undamaged control cells contain γ H2AX foci. Irradiation of control cells with 8 Gy of IR, to induce the formation of DNA double-strand breaks, results in a corresponding increase in cells with γ H2AX foci to 75% (Fig. 2A and 2B). Depletion of DDB1 also induces γ H2AX focus formation, with 67% of DDB1-depleted cells displaying intranuclear foci (Fig. 2A and 2B). Irradiation of DDB1-depleted cells further enhances the percentage with γ H2AX foci to 84% (Fig. 2B). The formation of γ H2AX foci in the majority of cells following depletion of DDB1 suggests that the loss of this protein generates DNA damage.

To further support the finding that depletion of DDB1 results in DNA damage, U2OS cells transfected with control or DDB1 siRNA were also examined for Mre11 focus formation. Mre11 is one component of the MRN (Mre11-Rad50-Nbs1) complex, which localizes to sites of double-strand breaks and facilitates repair of the damaged DNA (42). Immunostaining with γ H2AX and Mre11 reveals that the γ H2AX foci colocalize with Mre11 foci in the irradiated cells, as well as in the DDB1-depleted cells (Fig. 2A). This suggests that the γ H2AX foci do indeed represent sites of DNA damage, as proteins necessary for the repair of double-strand breaks are also recruited to these sites within the cell.

The extent of DNA damage was characterized by examining the number of γ H2AX foci generated per cell in control, irradiated, and DDB1-depleted cells. While 80% of control cells contained no γ H2AX foci, 90% of DDB1-depleted cells displayed γ H2AX foci ranging in numbers from 3 to 86, with an average of 22 γ H2AX foci per cell (Fig. 2C). In comparison, control cells display an average of one focus per cell, while




FIG. 2. DDB1 depletion results in γ H2AX, Mre11, and RPA focus formation. U2OS cells were transfected with control or DDB1 siRNA oligonucleotides. Cells transfected with control siRNA were also irradiated with 8 Gy of IR 2 hours prior to analysis where indicated. (A) Three days after siRNA transfection the cells were fixed and stained with antibodies to H2AX phospho-S139 and Mre11, followed by the appropriate FITC and rhodamine red-X secondary antibodies. The nucleus was visualized with DAPI. (B) The percentage of U2OS cells displaying five or more intranuclear γ H2AX foci 3 days after transfection with control or DDB1 siRNA oligonucleotides was quantified. (C) The number of γ H2AX foci per cell was quantitated. (D) Cells were fixed and stained with an antibody to RPA34. DAPI staining was used to visualize the nucleus.

those irradiated with the lethal dose of 8 Gy of IR display an average of 66 γ H2AX foci per cell (Fig. 2C).

In addition to monitoring γ H2AX and Mre11 focus formation as markers of DNA damage, we also examined RPA focus formation. RPA is a three-subunit protein complex that binds single-stranded DNA in eukaryotic cells and, like γ H2AX and Mre11, forms intranuclear foci after DNA damage (43). Immunostaining for the RPA34 subunit of this heterotrimeric protein complex indicates that similarly to irradiated cells, DDB1-depleted cells display numerous RPA34 foci (Fig. 2D). These results provide additional evidence that depletion of DDB1 results in DNA damage.

DDB1 maintains genome integrity as part of a Cul4A ubiquitin ligase complex. All currently known roles of DDB1 involve its functioning as part of a multiprotein complex containing Cul4A that targets substrates for ubiquitination (2, 26, 29, 54, 56, 64, 65, 70). To determine if defective ubiquitination contributes to the phenotype observed after DDB1 depletion, we used siRNA to deplete Cul4A. Depletion of Cul4A from HeLa cells results in the phosphorylation of Chk2 T68, anal-

ogous to what is observed following depletion of DDB1 (Fig. 3A). Similar phenotypes are also observed in the untransformed RPE-hTERT cells. Checkpoint activation is absent from undamaged RPE-hTERT cells treated with control siRNA and is induced following irradiation, as indicated by p53 S15 phosphorylation (Fig. 3B). The individual depletions of DDB1 and Cul4A result in p53 S15 phosphorylation and p21 induction in the absence of exogenous DNA damage, and further increases in p53 phosphorylation are observed after ionizing radiation (Fig. 3B). Additionally, depletion of Cul4A produces a modest increase in cells with 4n DNA content (see Fig. S1 in the supplemental material). This phenotype is reminiscent of that observed following DDB1 depletion and correlates with the phosphorylation of checkpoint proteins; however, the cell cycle arrest following depletion of Cul4A is less striking than the arrest typically observed following depletion of DDB1. This difference may be due to differences in the silencing efficiency of the siRNA oligonucleotides or may indicate that DDB1 is limiting in the DDB1-Cul4A ubiquitin ligase complex. The activation of checkpoint pathways follow-




FIG. 3. Depletion of Cul4A yields a DNA damage phenotype similar to that of DDB1 depletion. (A) HeLa cells were transfected with control, DDB1, or Cul4A siRNA oligonucleotides. Three days after transfection cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted with the indicated antibodies. (B) RPE-hTERT cells were transfected with control, DDB1, or Cul4A siRNA oligonucleotides. Three days after transfection the indicated samples were irradiated with 8 Gy of IR and incubated 2 hours prior to analysis. Checkpoint signaling was monitored by immunoblotting with the indicated antibodies.

ing depletion of Cul4A is consistent with the hypothesis that the DNA damage observed following depletion of DDB1 results from defective ubiquitination of a DDB1-Cul4A substrate(s).

Defective NER is not responsible for the DNA damage observed after DDB1 depletion. One way in which DDB1 may exert its genome protective function is through its role in NER (28, 29, 56, 61). Since the chromatin binding activity of the DDB1-DDB2-Cul4A ubiquitin ligase complex is important for the GGR subpathway of NER, we determined whether a defect in this repair process was the cause of the phenotype observed following DDB1 depletion (21, 30). To examine this possibility, we disrupted GGR by depleting DDB2. Depletion of DDB2 using siRNA oligonucleotides does not resemble the phenotype observed following depletion of DDB1 (Fig. 4A). ATM S1981 and Chk2 T68 phosphorylation, as well as increased p21 levels, is observed after depletion of DDB1 but is minimal after depletion of DDB2. Also, depletion of DDB2 does not cause a G₂ accumulation (see Fig. S2 in the supplemental material). We further examined the potential role that impaired GGR activity may have in contributing to the damage phenotype by depleting XPC, a damage sensor protein re-

quired for the GGR subpathway of NER (6, 55, 68). Loss of XPC function is more detrimental to GGR than the loss of DDB1-DDB2-Cul4A ubiquitin ligase activity (38). However, despite an effective reduction in protein levels (Fig. 4D), depletion of XPC by siRNA again does not produce the phenotypic characteristics of DDB1 depletion. ATM S1981 and Chk2 T68 phosphorylation is not observed following depletion of XPC from cells, nor is there a significant increase in p21 levels (Fig. 4B). Depletion of XPC also does not result in a G₂ accumulation of cells (see Fig. S2 in the supplemental material). These results suggest that defects in GGR are unlikely to be the cause of the DNA damage observed after DDB1 depletion.

In addition to functioning in the GGR subpathway of NER, DDB1 also has a role in TCR (21). The DDB1-Cul4A ubiquitin ligase complex functions independently of DDB2 in this capacity. To determine whether defective TCR contributes to the phenotype observed after DDB1 depletion, we depleted XPA using siRNA oligonucleotides. Like DDB1, XPA is required for both GGR and TCR, with the loss of this protein reducing the repair capacity of cells to approximately 10% (6, 38, 55). Depletion of XPA from cells does not produce a phenotype reminiscent of DDB1 depletion. There is no phosphorylation of checkpoint proteins, no increase in p21 levels, and no aberration in the cell cycle distribution of these cells (Fig. 4C; see also Fig. S2 in the supplemental material). Immunoblotting assays for XPA demonstrate that the siRNA oligonucleotides effectively reduce XPA protein levels in these experiments (Fig. 4D). These data indicate that the phenotype observed after depletion of DDB1 is not due to defective GGR or TCR.

Misregulation of Cdt1 contributes to the DNA damage observed following depletion of DDB1. Aside from its role in NER, another function ascribed to DDB1 is the regulation of Cdt1 by DDB1-Cul4A. The DDB1-Cul4A ubiquitin ligase complex targets this replication licensing factor for degradation following UV and IR damage (24, 26). It also regulates Cdt1 degradation during normal cell cycle progression in combination with an SCF ubiquitin ligase complex (2, 27, 45, 52). Regulation of Cdt1 is critical, as overexpression of this protein leads to rereplication of genomic DNA. During the course of characterizing the phenotype resulting from DDB1 depletion, it was apparent in the DNA content profiles generated by flow cytometry that depletion of DDB1 increases the percentage of cells with more than 4n DNA content (Fig. 5A). While only 4.5% of control cells reside in this population, 18.1% of DDB1-depleted cells display a DNA content greater than 4n. The existing link between DDB1-Cul4A and Cdt1 degradation suggests that the increase in the percentage of cells with more than 4n DNA content after DDB1 depletion may result from rereplication due to the misregulation of Cdt1. To more definitively determine whether DDB1 depletion causes rereplication, we monitored incorporation of the thymidine analogue BrdU by flow cytometry. Depletion of DDB1 from U2OS cells again enhanced the percentage of cells with greater than 4n DNA content (Fig. 5B). Furthermore, nearly 36% of DDB1-depleted cells with greater than 4n DNA content are actively undergoing DNA synthesis and incorporating BrdU (6% of the total DDB1-depleted population). DNA synthesis in cells with greater than 4n DNA content suggests that this population




FIG. 4. Disruption of NER does not cause activation of cell cycle checkpoint signaling. (A) Cells were transfected with control, DDB1, or DDB2 siRNA oligonucleotides. Three days after transfection cell lysates were harvested, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotted with the indicated antibodies. (B) Checkpoint activation was monitored on days 2, 3, and 4 after transfection with control, DDB1, and XPC siRNA oligonucleotides by immunoblotting with the indicated antibodies. (C) Cells were transfected with control, DDB1, or XPA siRNA oligonucleotides. Three days after transfection, checkpoint activation was examined by immunoblotting with the indicated antibodies. (D) The efficiency of depletion by the XPA and XPC siRNA oligonucleotides was monitored by immunoblot analysis. The asterisks denote nonspecific, cross-reacting proteins.

does arise from rereplication. The presence of active cell cycle checkpoints has likely limited the extent of BrdU incorporation in the DDB1-depleted cells displaying greater than 4n DNA content, as well as in some S-phase cells, as evidenced by the diminished BrdU incorporation in cells possessing a DNA content between 2n and 4n. The cells with greater than 4n DNA content after DDB1 depletion are unlikely to result from defects in cytokinesis, since we found no enhancement in the number of multinucleated cells in the DDB1-depleted population (see Fig. S3 in the supplemental material).

The presence of rereplication in DDB1-depleted cells sug-

gests that regulation of the replication licensing factor Cdt1, a known substrate of the DDB1-Cul4A ubiquitin ligase complex, may be disrupted. Consistent with this interpretation, we observed an increase in the abundance of Cdt1 protein in the DDB1-depleted cell population (Fig. 5C). Furthermore, the Cdt1 protein is more stable in the DDB1-depleted cells (approximate half-life of 120 min) than in control cells (approximate half-life of 65 min) (Fig. 5D). Thus, Cdt1 turnover is misregulated in DDB1-depleted cells.

The increased stability of Cdt1 and the rereplication observed following DDB1 depletion suggest that misregulation of




FIG. 5. Misregulation of Cdt1 contributes to the damage observed following DDB1 depletion. (A) The DNA content of HeLa cells was analyzed by flow cytometry following propidium iodide staining 4 days after transfection with control or DDB1 siRNA oligonucleotides. Cell cycle distributions were quantified using FlowJo fluorescence-activated cell sorting analysis software. (B) U2OS cells were transfected with control or DDB1 siRNA oligonucleotides. Four days after transfection the cells were labeled with BrdU. After fixation, the cells were immunostained with an anti-BrdU antibody and DNA content was monitored by flow cytometry using propidium iodide staining. (C) U2OS cells were transfected with control, Cdt1, and DDB1 siRNA oligonucleotides alone or in combination, as indicated. Cdt1 abundance and checkpoint activation were examined 4 days after transfection by immunoblotting with the indicated antibodies. (D) Cells stably expressing an HA-tagged Cdt1 protein were transfected with control or DDB1 siRNA oligonucleotides. Two days after transfection cells were treated with 100 μ M cycloheximide (CHX) and harvested at the times indicated. Depletion of DDB1 and the stability of Cdt1 were monitored by immunoblot analyses. (E and F) U2OS cells were transfected with control, Cdt1, and DDB1 siRNA oligonucleotides alone or in combination, as indicated. (E) The extent of rereplication and G₂ accumulation were monitored by flow cytometric analysis of DNA content. Quantitation was performed using the FlowJo software analysis program. (F) Intranuclear γ H2AX focus formation was examined by indirect immunofluorescence. The graph depicts the percentage of cells in each population displaying γ H2AX foci.

Cdt1 may be contributing to the phenotype observed in DDB1-depleted cells. To examine this possibility, we used siRNA to codeplete Cdt1 and DDB1 from U2OS cells. If deregulation of Cdt1 is promoting rereplication in DDB1-depleted cells, then depletion of Cdt1 with siRNA should reduce the percentage of cells with greater than 4n DNA content. The level of Cdt1 depletion that was achieved in combination with a control siRNA did not alter the cell cycle profile, the percentage of replicating cells, or the percentage of cells with more than 4n DNA content (Fig. 5E and data not shown). In contrast, codepletion of Cdt1 with DDB1 reduces the percentage of cells with more than 4n DNA content from 14% to 5%, a level similar to that observed in control cells (Fig. 5E). This confirms that the population of cells with greater than 4n DNA content after DDB1 depletion does represent cells in which rereplication has occurred due to Cdt1 misregulation.

Since codepletion of Cdt1 with DDB1 can reduce the percentage of rereplicating cells, we next asked whether the codepletion of Cdt1 with DDB1 can alleviate the DNA damage and checkpoint activation caused by DDB1 depletion. As observed previously, depletion of DDB1 significantly enhances the percentage of cells displaying γ H2AX foci. The codepletion of DDB1 with Cdt1 considerably reduces the amount of DNA damage generated by the loss of DDB1, as the percentage of cells with γ H2AX foci was reduced by nearly 50% (Fig. 5F). A similar alleviation in the DNA damage phenotype was observed by immunoblot analysis. As noted previously, depletion of DDB1 results in phosphorylation of p53 S15 and Chk2 T68 (Fig. 5C). These events are not observed in control or Cdt1-depleted cells. When DDB1 is depleted in combination with Cdt1, the levels of phosphorylated p53 S15 and Chk2 T68 are significantly reduced (Fig. 5C). Collectively, these results indicate that misregulation of Cdt1, and the subsequent rereplication, contributes to the formation of DNA damage and the activation of checkpoint responses after DDB1 depletion. It should also be noted that reducing the level of Cdt1 below that of control cells only partially alleviates the DNA damage associated with DDB1 depletion. Thus, misregulation of Cdt1 may be only one of the factors that cause DNA damage in DDB1-depleted cells.

Disruption of SCF^{Skp2}-mediated Cdt1 regulation does not cause DNA damage. Multiple mechanisms of Cdt1 regulation exist, and our results suggest that disruption of a single mechanism is sufficient to cause deregulation of Cdt1, rereplication, and DNA damage. To more precisely examine the ubiquitin-dependent mechanisms of Cdt1 regulation and their potential to generate DNA damage when disrupted, we transiently expressed wild-type Cdt1 or Cdt1 mutants where one or both of the ubiquitin-mediated degradation pathways were abrogated. Disruption of the DDB1-Cul4A-dependent ubiquitination was accomplished by mutating residues of Cdt1 that are critical for its interaction with the DNA polymerase processivity factor PCNA (Q3A, V6A, F9A, F10A = Δ PIP). Binding of Cdt1 to PCNA is required for degradation of Cdt1 by DDB1-Cul4A (2, 27, 45, 52). We also disrupted the SCF^{Skp2} ubiquitination pathway for Cdt1 by removing a cyclin-dependent kinase (CDK) phosphorylation site in Cdt1 at threonine 29 (T29A). The binding and degradation of Cdt1 by SCF^{Skp2} require the prior phosphorylation of Cdt1 on T29 by CDKs (34, 36, 57, 60). Introduction of an empty vector into HeLa cells does not cause




FIG. 6. Disruption of SCF^{Skp2}-dependent Cdt1 degradation does not generate DNA damage. (A) HeLa cells were transfected with an empty vector or vectors encoding wild-type (wt) Cdt1; Cdt1 Q3A, V6A, F9A, and F10A (Δ PIP); or Cdt1 T29A. Checkpoint activation was examined in these cells 2 days after transfection by immunoblotting. (B) HeLa cells were transfected with control, DDB1, or Skp2 siRNA oligonucleotides. Three days after transfection cell lysates were harvested and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and checkpoint activation was monitored by immunoblotting with the indicated antibodies.

DNA damage; however, overexpression of a wild-type Cdt1 protein induces DNA damage signaling (Fig. 6A), as previously reported (33, 41, 66, 74). A similar level of p53 S15 phosphorylation is observed upon disruption of the SCF^{Skp2} degradation pathway (T29A), indicating that the loss of this regulatory mechanism does not cause any further damage than overexpression of wild-type Cdt1 does. Notably, disruption of DDB1-Cul4A-dependent Cdt1 degradation (Δ PIP) resulted in




FIG. 7. Cell cycle progression is required for the accumulation of DNA damage in DDB1-depleted cells. RPE-hTERT cells were transfected with control or DDB1 siRNA oligonucleotides. Cells were arrested by growth to confluence, arrested, and released back into the cell cycle by splitting them into subconfluent densities or maintained at subconfluent densities during the course of the experiment. All samples were harvested on the fourth day after siRNA transfection, and DNA content was measured by flow cytometry of propidium iodide-stained cells (A) or cell lysates were prepared and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and checkpoint activation was monitored by immunoblotting (B).

greater p53 S15 phosphorylation than did overexpression of either wild-type Cdt1 or the T29A mutant. This suggests that the two ubiquitin-dependent mechanisms of Cdt1 degradation are not redundant but that disruption specifically of the DDB1-Cul4A-mediated Cdt1 degradation pathway has a greater potential to generate DNA damage.

To further examine the ability of these ubiquitin ligase complexes to maintain genome stability, we assessed checkpoint activation following depletion of DDB1 or Skp2 by siRNA. While depletion of DDB1 results in the phosphorylation of Chk1 S345, Chk2 T68, and p53 S15, these markers of DNA damage signaling are not observed following depletion of Skp2 (Fig. 6B). Interestingly, depletion of DDB1 elevates Cdt1 levels to a greater extent than that observed following depletion of Skp2, suggesting that disruption of the DDB1-Cul4A ubiquitin ligase complex is more detrimental to the proper regulation of Cdt1 protein levels than loss of the SCF^{Skp2} ubiquitin ligase complex. Together, these results support our conclusion that misregulation of Cdt1 generates DNA damage and suggests that disruption of DDB1-Cul4A-mediated Cdt1 degradation is more detrimental to genome stability than disruption of the SCF^{Skp2}-mediated degradation pathway.

Accumulation of DNA damage following DDB1 depletion requires cell cycle progression. To further test the model that re-replication resulting from misregulation of Cdt1 is contributing to the phenotype observed after DDB1 depletion, we examined the cell cycle dependency of the phenotype. If our model is correct, then the accumulation of DNA damage should require progression into S phase. RPE-hTERT cells were treated with control or DDB1 siRNA and grown to confluence as a means of causing contact inhibition and a G₀ arrest. Cell cycle analysis by propidium iodide staining shows a

significant accumulation of cells with a 2n DNA content following the arrest by contact inhibition (Fig. 7A). Approximately 93% of control cells and 88% of DDB1-depleted cells arrested by this method display a DNA content of 2n. G₀-arrested cells were also released into the cell cycle and harvested at a point in time when cells were advancing into S phase. This population allows us to examine the extent of DNA damage that occurs during progression through a single S phase. It should be noted, however, that DDB1-depleted cells take more time to be released from a G₀ arrest and do not release as synchronously as control cells (Fig. 7A). Finally, control and DDB1-depleted cells were allowed to cycle unperturbed throughout the course of the experiment. The extent of DNA damage signaling in these samples was then examined by immunoblotting. DDB1-depleted cells that are arrested by contact inhibition show very little p53 S15 phosphorylation or p21 induction (Fig. 7B). The entrance of DDB1-depleted cells into S phase corresponds with an increase in the levels of p53 S15 phosphorylation and p21 induction, whereas the analogous control cells showed no increase in these markers of DNA damage. While it is unclear why DDB1-depleted cells are released slowly from G₀, these data indicate that the damage observed after DDB1 depletion can occur during a single cell cycle and that the damage requires progression into S phase. Cells depleted of DDB1 that are allowed to cycle during the course of the experiment show further increases in p53 S15 phosphorylation and p21 induction, suggesting that the damage is accumulating and further activating checkpoint responses over time. Cyclin A immunoblotting of these samples was used as a marker of S and G₂ phases of the cell cycle and corresponds with the flow cytometry data (Fig. 7B).




FIG. 8. Depletion of DDB1 enhances chromosome breaks. (A) U2OS cells were transfected with control or DDB1 siRNA oligonucleotides and processed for metaphase spread analysis 3 days after transfection. Fragile sites were induced by the addition of 0.1 μ M aphidicolin (Aph) 24 h prior to harvest. Identification of chromosome gaps and breaks was facilitated by trypsin-Giemsa banding, as shown in the inset. The arrowhead indicates the location of a chromosome break. The graph depicts the average number of chromosome gaps or breaks per cell. (B) The chromosome location of the gaps and breaks was recorded based on banding patterns. FRA3B, FRA2G, and FRA16D breakages were scored as described previously (48).

Analysis of the location of chromosomal breaks in DDB1-depleted cells.

Our data indicate that lack of DDB1 function causes DNA damage, partially through deregulation of Cdt1 that allows rereplication to occur. Since the DNA damage is associated with replication, we hypothesized that the double-strand breaks may preferentially occur at chromosomal fragile sites. These chromosome regions are particularly vulnerable to breakage, especially when cells experience replication stress such as that caused by low doses of aphidicolin (18, 48). Therefore, we examined whether the DNA double-strand breaks that form following DDB1 depletion occur preferentially at fragile sites. Metaphase spreads from U2OS cells treated with a control siRNA or DDB1 siRNA were analyzed for chromosomal gaps and breaks by trypsin-Giemsa banding. Depletion of DDB1 from U2OS cells enhances the occurrence of chromosomal gaps and breaks in mitotic cells more than twofold over the number of events observed in control cells (Fig. 8A). This increase is similar to what we observed upon treating cells with aphidicolin. Interestingly, treatment of DDB1-depleted cells with aphidicolin merely caused an additive effect. Further characterization of the location of these chromosomal breaks reveals that while the addition of aphidicolin enhances breakage events at common fragile sites, such as FRA3B, depletion of DDB1 alone causes breakage events to occur at a wide variety of loci throughout the genome, with no enhancement in the number of breaks at any known fragile site (Fig. 8B). For example, over 10% of breaks in aphidicolin-treated cells occur at a single fragile site (FRA3B), but only 0.7% of breaks caused by DDB1 depletion were at this site. These results were replicated in the untransformed RPE-hTERT cells, where depletion of DDB1 again enhanced the number of chromosome breakage events observed relative to control cells (data not shown). These data indicate that the cause of the double-strand breaks in DDB1-depleted cells is distinct from the replication problems created by aphidicolin and suggest that rereplication does not cause DNA damage due to the stalling of replication forks at fragile sites.

DISCUSSION

Our data indicate that DDB1 is required for maintaining genome stability in human cells. Silencing of DDB1 expression results in an accumulation of DNA damage and activation of cell cycle checkpoints. DDB1 protects the integrity of the genome as part of an E3 ubiquitin ligase complex containing Cul4A. One target of this complex that must be degraded to preserve genome integrity is the replication licensing factor Cdt1. Multiple levels of Cdt1 regulation exist in human cells. These mechanisms possess unique and necessary roles in the regulation of Cdt1, to properly restrain this protein and prevent the adverse cellular consequences associated with its misregulation.

A role for DDB1 in maintaining genome stability has previously been noted in other organisms. Shimanouchi and colleagues found that depletion of DDB1 in *Drosophila melanogaster* promoted the loss of heterozygosity in somatic cells (53). Holmberg et al. also found that deletion of DDB1 in *S. pombe* enhances the mutation rate more than 20-fold (25). These data correlate well with our data from human cells. Depletion or deletion of DDB1 results in genome instability, as assessed by the generation of DNA double-strand breaks in human cells (this study) or an enhanced mutation rate in yeast, and in neither organism is this instability the result of defective NER. In *S. pombe*, the genetic instability associated with deletion of DDB1 could be partially suppressed by removing Spd1, an inhibitor of RNR (25). DDB1 and Pcu4 (the Cul4 homologue in yeast) promote the ubiquitin-mediated degradation of Spd1 to allow association of the RNR subunits and production of deoxynucleoside triphosphates for DNA synthesis and repair (8, 12, 25, 35). A human homologue of Spd1 has not been identified; therefore, it is unclear whether this function of DDB1 is conserved in higher eukaryotes. However, removal of Spd1 could not completely alleviate the genetic instability created by the loss of DDB1 in *S. pombe*. This suggests that DDB1 is required for other aspects of mutation avoidance in addition to regulating DNA replication through the degradation of

Spd1. Likewise, we suggest that human DDB1 mediates genome stability, in part by controlling DNA replication through the degradation of Cdt1. However, the inability of Cdt1 depletion to completely alleviate the phenotype observed following DDB1 depletion indicates that additional functions of DDB1 are critical for its role in the maintenance of genome integrity.

The DDB1-Cul4A ubiquitin ligase complex regulates DNA replication in multicellular eukaryotes by mediating the degradation of Cdt1. Exposure to exogenous DNA-damaging agents induces the destruction of Cdt1 specifically by DDB1-Cul4A (24, 26). Our data indicate that DDB1 also has an important role in the regulation of Cdt1 in the absence of exogenous DNA damage. In agreement with our proposal, recent reports have implicated DDB1-Cul4A in the replication-dependent degradation of Cdt1 and identified PCNA as a critical mediator of the DDB1-Cul4A-dependent Cdt1 ubiquitination (2, 27, 45, 52). The destruction of Cdt1 by the DDB1-Cul4A ubiquitin ligase complex is one of three mechanisms known in human cells to regulate Cdt1. Additionally, the replication-dependent degradation of this protein can be accomplished by an SCF^{Skp2} ubiquitin ligase complex, which is targeted to Cdt1 by a CDK-mediated phosphorylation event (34, 36, 57, 60). Cdt1 is also functionally inhibited by the binding of geminin (59, 71). These multiple levels of Cdt1 regulation suggest that the proper restraint of this protein activity is crucial.

Disruption of Cdt1 regulation is detrimental to genome stability and cell viability (25, 41, 53). Highly elevated levels of Cdt1 expression lead to significant amounts of rereplication in human cells, *Drosophila*, and *Xenopus laevis* (3, 33, 62, 66). Rereplication induces activation of DNA damage response pathways in humans, *Xenopus*, and yeast (20, 33, 41, 66, 74). The phenotype observed after DDB1 depletion is consistent with the phenotype observed after rereplication. We found a significant increase in DNA damage and activation of both ATR- and ATM-mediated damage response pathways (Fig. 1 and 2). Notably, we see this enhancement of genome instability with only moderate increases in Cdt1 levels (Fig. 5C), in contrast to the significantly greater levels of Cdt1 overexpression that were used in previous studies. Furthermore, we observe direct evidence that rereplication is occurring in DDB1-depleted cells with the incorporation of BrdU by cells with greater than 4n DNA content (Fig. 5B). The rereplication observed after DDB1 depletion is not extensive, perhaps due in part to the restraints imposed by the checkpoint response (33). The elevated levels of Cdt1 protein, rereplication, and DNA damage suggest that misregulation of Cdt1 is contributing to the phenotype observed after DDB1 depletion. In support of this hypothesis, we found that there was indeed deregulation of Cdt1, as the degradation of Cdt1 proteins was significantly delayed following depletion of DDB1 (Fig. 5D). Additionally, reducing Cdt1 protein levels in DDB1-depleted cells could prevent rereplication and eliminate approximately half of the DNA damage and checkpoint activation (Fig. 5). Importantly, the level of Cdt1 reduction achieved in these experiments did not interfere with normal DNA replication. Therefore, the reduction in DNA damage by codepleting Cdt1 with DDB1 is unlikely to be an indirect consequence of slowing the cell cycle. Our results clearly demonstrate that depletion of DDB1 results in the misregulation of Cdt1, which stabilizes and elevates the cellular levels of this protein. The consequence of this misregulation is rereplication,

which contributes to the DNA damage and checkpoint activation observed after DDB1 depletion.

Our data indicate that rereplication occurs in DDB1-depleted cells despite the presence of other mechanisms that operate to suppress the refiring of replication origins. Previous data from human systems have suggested that the DDB1-Cul4 and SCF^{Skp2} mechanisms of Cdt1 destruction are redundant in the absence of exogenous DNA damage (45, 52). However, the disruption of a single mode of Cdt1 regulation in other organisms was shown to be sufficient to have adverse effects. In *Xenopus*, disruption of the DDB1-Cul4 degradation pathway stabilizes Cdt1 and induces significant levels of rereplication (2). Depletion of Cul4 from *Caenorhabditis elegans* also stabilizes Cdt1 and results in massive rereplication, with cells exhibiting up to 100n DNA content (73). The stabilization of Cdt1 and the presence of rereplication after DDB1 depletion argue against redundant roles for DDB1-Cul4A and SCF^{Skp2} in the destruction of Cdt1 in human cells. Additionally, this suggestion is supported by our observation that expression of a Cdt1 mutant insensitive to DDB1-Cul4A degradation results in greater DNA damage than expression of either wild-type Cdt1 or a mutant that is insensitive to the SCF^{Skp2} destruction pathway (Fig. 6A). We propose that the DDB1-dependent degradation of Cdt1 is particularly important because the loss of DDB1 creates a situation in which one other mechanism of Cdt1 regulation is also inactivated. Depletion of DDB1 generates DNA damage that activates cell cycle checkpoints, which in turn function to inactivate CDK complexes (50). Since the SCF^{Skp2}-mediated destruction of Cdt1 requires a CDK-mediated phosphorylation event, this pathway is inhibited by the presence of active checkpoints. Therefore, disruption of DDB1 eliminates both ubiquitin-dependent mechanisms of Cdt1 regulation, which will likely result in further rereplication, greater DNA damage, and amplification of genome instability (Fig. 9). It should be noted that cells generate DNA damage intrinsically as a consequence of respiration and DNA metabolism. Replication forks encounter DNA lesions and experience difficulty in replicating through specific regions of the genome during every round of DNA synthesis. The act of growing cells in culture can also increase cellular stresses. Thus, the distinction between DNA damage-dependent Cdt1 degradation and replication-dependent degradation is largely one of degree.

DDB1-dependent regulation of Cdt1 is not sufficient to explain all of the genome instability that arises from DDB1 depletion. Codepletion of Cdt1 with DDB1 eliminates rereplication; however, it does not completely prevent DNA damage or checkpoint activation. Additional genome maintenance functions of DDB1 likely have cell cycle dependency, since the loss of DDB1 from G₀-arrested cells does not cause DNA damage (Fig. 7). Identifying other substrates of DDB1-Cul4A whose degradation is important in preventing genetic instability will be important. Another question that remains unanswered is the mechanism by which rereplication activates checkpoint pathways. Our analyses suggest that rereplication causes DNA double-strand breaks in a manner that is distinct from those arising at chromosome fragile sites during replication stress. It is unclear whether these breaks are at random locations or whether they may cluster near specific genomic regions that are prone to rereplication. The breaks do not appear to cluster near centromeres. This suggests that attach-




FIG. 9. Model highlighting the importance of DDB1 in Cdt1 regulation. (A) Geminin, DDB1-Cul4A, and SCF^{Skp2} cooperate to restrain the activity and levels of Cdt1, ensuring that origins of replication fire only once per S phase. (B) siRNA depletion of DDB1 disrupts the DDB1-Cul4A-dependent regulation of Cdt1 and causes DNA damage due to rereplication and impaired regulation of an additional unidentified substrate. DNA damage activates cell cycle checkpoints, which in turn function to inactivate CDK complexes. SCF^{Skp2}-mediated degradation of Cdt1 requires a prior phosphorylation event by CDK; therefore, this mechanism of Cdt1 regulation is disrupted by the presence of active checkpoints. The deregulation results in increased Cdt1 levels that promote rereplication, leading to greater DNA damage, and amplification of genomic instability.

ment of the mitotic spindle to a rereplicated centromere on a single chromatid, and the subsequent breakage of the chromosome during anaphase, is not a major mechanism contributing to these breaks. One possibility is that rereplication causes double-strand breaks as the second fork originating from a refired origin encounters the Okazaki fragments generated by the original replication fork. A second possibility is that the forks initiated at a refired origin are defective, stall, and eventually collapse, thus generating DNA damage.

Recent studies have highlighted a role for replication stress as an early event in the initiation of cancer (5, 19, 67). Aberrant DNA replication in precancerous lesions produces DNA damage and activates checkpoint pathways. Inactivation of these damage response pathways is associated with tumor progression due to genetic instability. Disruption of DDB1-dependent functions also has the ability to create replication stress and genetic instability, perhaps providing an avenue through which cancer progression can be facilitated. Changes in the activity of the DDB1-Cul4A ubiquitin ligase complex, or in mechanisms

regulating replication origin firing, may therefore play important roles in the process of tumorigenesis.

ACKNOWLEDGMENTS

This work was supported by a National Cancer Institute grant to D.C. D.C. is also supported by the Pew Scholars Program in the Biological Sciences, sponsored by the Pew Charitable Trusts. C.L. is supported by a Department of Defense predoctoral fellowship.

We thank Jeffrey Salisbury, Xiaohua Wu, and Yue Xiong for reagents.

REFERENCES

1. Abraham, R. T. 2004. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. *DNA Repair (Amsterdam)* **3**:883-887.
2. Arias, E. E., and J. C. Walter. 2006. PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication. *Nat. Cell Biol.* **8**:84-90.
3. Arias, E. E., and J. C. Walter. 2005. Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in *Xenopus* egg extracts. *Genes Dev.* **19**:114-126.
4. Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. *Science* **281**:1674-1677.
5. Bartkova, J., Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas, and J. Bartek. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**:864-870.
6. Berg, R. J., H. J. Ruven, A. T. Sands, F. R. de Grujil, and L. H. Mullenders. 1998. Defective global genome repair in XPC mice is associated with skin cancer susceptibility but not with sensitivity to UVB induced erythema and edema. *J. Invest. Dermatol.* **110**:405-409.
7. Blow, J. J., and A. Dutta. 2005. Preventing re-replication of chromosomal DNA. *Nat. Rev. Mol. Cell Biol.* **6**:476-486.
8. Bondar, T., A. Ponomarev, and P. Raychaudhuri. 2004. Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage. *J. Biol. Chem.* **279**:9937-9943.
9. Brown, A. L., C. H. Lee, J. K. Schwarz, N. Mitiku, H. Piwnica-Worms, and J. H. Chung. 1999. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc. Natl. Acad. Sci. USA* **96**:3745-3750.
10. Brown, E. J., and D. Baltimore. 2003. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. *Genes Dev.* **17**:615-628.
11. Canman, C. E., D. S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science* **281**:1677-1679.
12. Chabes, A., and L. Thelander. 2000. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. *J. Biol. Chem.* **275**:17747-17753.
13. Chen, X., Y. Zhang, L. Douglas, and P. Zhou. 2001. UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation. *J. Biol. Chem.* **276**:48175-48182.
14. Chu, G., and E. Chang. 1988. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. *Science* **242**:564-567.
15. Cleaver, J. E. 2005. Cancer in xeroderma pigmentosum and related disorders of DNA repair. *Nat. Rev. Cancer* **5**:564-573.
16. Cortez, D., S. Guntuku, J. Qin, and S. J. Elledge. 2001. ATR and ATRIP: partners in checkpoint signaling. *Science* **294**:1713-1716.
17. Diffley, J. F. 2004. Regulation of early events in chromosome replication. *Curr. Biol.* **14**:R778-R786.
18. Glover, T. W., M. F. Arlt, A. M. Casper, and S. G. Durkin. 2005. Mechanisms of common fragile site instability. *Hum. Mol. Genet.* **14**(Spec. No. 2):R197-R205.
19. Gorgoulis, V. G., L. V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R. A. Dittullo, Jr., N. G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, M. Herlyn, C. Kittas, and T. D. Halazonetis. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**:907-913.
20. Green, B. M., and J. J. Li. 2005. Loss of rereplication control in *Saccharomyces cerevisiae* results in extensive DNA damage. *Mol. Biol. Cell* **16**:421-432.
21. Groisman, R., J. Polanowska, I. Kuraoka, J. Sawada, M. Saijo, R. Drapkin, A. F. Kisselev, K. Tanaka, and Y. Nakatani. 2003. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. *Cell* **113**:357-367.
22. Guo, Z., A. Kumagai, S. X. Wang, and W. G. Dunphy. 2000. Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA

- replication blocks and UV-damaged DNA in *Xenopus* egg extracts. *Genes Dev.* **14**:2745–2756.
23. Gurley, L. R., J. A. D'Anna, S. S. Barham, L. L. Deaven, and R. A. Tobey. 1978. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. *Eur. J. Biochem.* **84**:1–15.
 24. Higa, L. A., I. S. Mihaylov, D. P. Banks, J. Zheng, and H. Zhang. 2003. Radiation-mediated proteolysis of CDT1 by CUL4-ROCI and CSN complexes constitutes a new checkpoint. *Nat. Cell Biol.* **5**:1008–1015.
 25. Holmberg, C., O. Fleck, H. A. Hansen, C. Liu, R. Slaaby, A. M. Carr, and O. Nielsen. 2005. Ddb1 controls genome stability and meiosis in fission yeast. *Genes Dev.* **19**:853–862.
 26. Hu, J., C. M. McCall, T. Ohta, and Y. Xiong. 2004. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROCI ligase in response to DNA damage. *Nat. Cell Biol.* **6**:1003–1009.
 27. Hu, J., and Y. Xiong. 2006. An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage. *J. Biol. Chem.* **281**:3753–3756.
 28. Hwang, B. J., J. M. Ford, P. C. Hanawalt, and G. Chu. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc. Natl. Acad. Sci. USA* **96**:424–428.
 29. Kapetanaki, M. G., J. Guerrero-Santoro, D. C. Bisi, C. L. Hsieh, V. Raptic-Otrin, and A. S. Levine. 2006. The DDB1-CUL4A-DDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. *Proc. Natl. Acad. Sci. USA* **103**:2588–2593.
 30. Keeney, S., A. P. Eker, T. Brody, W. Vermeulen, D. Bootsma, J. H. Hoeijmakers, and S. Linn. 1994. Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. *Proc. Natl. Acad. Sci. USA* **91**:4053–4056.
 31. Kumagai, A., J. Lee, H. Y. Yoo, and W. G. Dunphy. 2006. TopBP1 activates the ATR-ATRIP complex. *Cell* **124**:943–955.
 32. Lau, C. C., and A. B. Pardee. 1982. Mechanism by which caffeine potentiates lethality of nitrogen mustard. *Proc. Natl. Acad. Sci. USA* **79**:2942–2946.
 33. Li, A., and J. J. Blow. 2005. Cdt1 downregulation by proteolysis and geminin inhibition prevents DNA re-replication in *Xenopus*. *EMBO J.* **24**:395–404.
 34. Li, X., Q. Zhao, R. Liao, P. Sun, and X. Wu. 2003. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. *J. Biol. Chem.* **278**:30854–30858.
 35. Liu, C., K. A. Powell, K. Mundt, L. Wu, A. M. Carr, and T. Caspari. 2003. Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. *Genes Dev.* **17**:1130–1140.
 36. Liu, E., X. Li, F. Yan, Q. Zhao, and X. Wu. 2004. Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation. *J. Biol. Chem.* **279**:17283–17288.
 37. Liu, Q., S. Guntuku, X. S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, L. A. Donehower, and S. J. Elledge. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G₂/M DNA damage checkpoint. *Genes Dev.* **14**:1448–1459.
 38. Magnaldo, T., and A. Sarasin. 2004. Xeroderma pigmentosum: from symptoms and genetics to gene-based skin therapy. *Cells Tissues Organs* **177**:189–198.
 39. Matsuda, N., K. Azuma, M. Saijo, S. Iemura, Y. Hioki, T. Natsume, T. Chiba, K. Tanaka, and K. Tanaka. 2005. DDB2, the xeroderma pigmentosum group E gene product, is directly ubiquitylated by cullin 4A-based ubiquitin ligase complex. *DNA Repair (Amsterdam)* **4**:537–545.
 40. Matsuoka, S., M. Huang, and S. J. Elledge. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science* **282**:1893–1897.
 41. Melixetian, M., A. Ballabeni, L. Masiero, P. Gasparini, R. Zamponi, J. Bartek, J. Lukas, and K. Helin. 2004. Loss of geminin induces rereplication in the presence of functional p53. *J. Cell Biol.* **165**:473–482.
 42. Mirzoeva, O. K., and J. H. Petrini. 2001. DNA damage-dependent nuclear dynamics of the Mre11 complex. *Mol. Cell. Biol.* **21**:281–288.
 43. Myers, J. S., and D. Cortez. 2006. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. *J. Biol. Chem.* **281**:9346–9350.
 44. Nag, A., T. Bondar, S. Shiv, and P. Raychaudhuri. 2001. The xeroderma pigmentosum group E gene product DDB2 is a specific target of cullin 4A in mammalian cells. *Mol. Cell. Biol.* **21**:6738–6747.
 45. Nishitani, H., N. Sugimoto, V. Roukos, Y. Nakanishi, M. Saijo, C. Obuse, T. Tsurimoto, K. I. Nakayama, K. Nakayama, M. Fujita, Z. Lygerou, and T. Nishimoto. 2006. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. *EMBO J.* **25**:1126–1136.
 46. Paull, T. T., E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Gellert, and W. M. Bonner. 2000. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr. Biol.* **10**:886–895.
 47. Raptic-Otrin, V., V. Navazza, T. Nardo, E. Botta, M. McLenigan, D. C. Bisi, A. S. Levine, and M. Stefanini. 2003. True XP group E patients have a defective UV-damaged DNA binding protein complex and mutations in DDB2 which reveal the functional domains of its p48 product. *Hum. Mol. Genet.* **12**:1507–1522.
 48. Richards, R. I. 2001. Fragile and unstable chromosomes in cancer: causes and consequences. *Trends Genet.* **17**:339–345.
 49. Rogakou, E. P., C. Boon, C. Redon, and W. M. Bonner. 1999. Megabase chromatin domains involved in DNA double-strand breaks in vivo. *J. Cell Biol.* **146**:905–916.
 50. Sancar, A., L. A. Lindsey-Boltz, K. Unsal-Kacmaz, and S. Linn. 2004. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu. Rev. Biochem.* **73**:39–85.
 51. Schlegel, R., and A. B. Pardee. 1986. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. *Science* **232**:1264–1266.
 52. Senga, T., U. Sivaprasad, W. Zhu, J. H. Park, E. E. Arias, J. C. Walter, and A. Dutta. 2006. PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination. *J. Biol. Chem.* **281**:6246–6252.
 53. Shimanouchi, K., K. Takata, M. Yamaguchi, S. Murakami, G. Ishikawa, R. Takeuchi, Y. Kanai, T. Ruike, R. Nakamura, Y. Abe, and K. Sakaguchi. 2006. Drosophila damaged DNA binding protein 1 contributes to genome stability in somatic cells. *J. Biochem. (Tokyo)* **139**:51–58.
 54. Shyanov, P., A. Nag, and P. Raychaudhuri. 1999. Cullin 4A associates with the UV-damaged DNA-binding protein DDB. *J. Biol. Chem.* **274**:35309–35312.
 55. Sugawara, K., J. M. Ng, C. Masutani, S. Iwai, P. J. van der Spek, A. P. Eker, F. Hanaoka, D. Bootsma, and J. H. Hoeijmakers. 1998. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. *Mol. Cell* **2**:223–232.
 56. Sugawara, K., Y. Okuda, M. Saijo, R. Nishi, N. Matsuda, G. Chu, T. Mori, S. Iwai, K. Tanaka, K. Tanaka, and F. Hanaoka. 2005. UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. *Cell* **121**:387–400.
 57. Sugimoto, N., Y. Tatsumi, T. Tsurumi, A. Matsukage, T. Kiyono, H. Nishitani, and M. Fujita. 2004. Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding. *J. Biol. Chem.* **279**:19691–19697.
 58. Svoboda, D. L., L. P. Briley, and J. M. Vos. 1998. Defective bypass replication of a leading strand cyclobutane thymine dimer in xeroderma pigmentosum variant cell extracts. *Cancer Res.* **58**:2445–2448.
 59. Tada, S., A. Li, D. Maiorano, M. Mechali, and J. J. Blow. 2001. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. *Nat. Cell Biol.* **3**:107–113.
 60. Takeda, D. Y., J. D. Parvin, and A. Dutta. 2005. Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. *J. Biol. Chem.* **280**:23416–23423.
 61. Tang, J. Y., B. J. Hwang, J. M. Ford, P. C. Hanawalt, and G. Chu. 2000. Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. *Mol. Cell* **5**:737–744.
 62. Thomer, M., N. R. May, B. D. Aggarwal, G. Kwok, and B. R. Calvi. 2004. Drosophila double-parked is sufficient to induce re-replication during development and is regulated by cyclin E/CDK2. *Development* **131**:4807–4818.
 63. Tibbetts, R. S., K. M. Brumbaugh, J. M. Williams, J. N. Sarkaria, W. A. Cliby, S. Y. Shieh, Y. Taya, C. Prives, and R. T. Abraham. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. *Genes Dev.* **13**:152–157.
 64. Ulane, C. M., and C. M. Horvath. 2002. Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. *Virology* **304**:160–166.
 65. Ulane, C. M., J. J. Rodriguez, J. P. Parisien, and C. M. Horvath. 2003. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. *J. Virol.* **77**:6385–6393.
 66. Vaziri, C., S. Saxena, Y. Jeon, C. Lee, K. Murata, Y. Machida, N. Wagle, D. S. Hwang, and A. Dutta. 2003. A p53-dependent checkpoint pathway prevents rereplication. *Mol. Cell* **11**:997–1008.
 67. Venkitaraman, A. R. 2005. Medicine: aborting the birth of cancer. *Nature* **434**:829–830.
 68. Volker, M., M. J. Mone, P. Karmakar, A. van Hoffen, W. Schul, W. Vermeulen, J. H. Hoeijmakers, R. van Driel, A. A. van Zeeland, and L. H. Mullenders. 2001. Sequential assembly of the nucleotide excision repair factors in vivo. *Mol. Cell* **8**:213–224.
 69. Ward, I. M., and J. Chen. 2001. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J. Biol. Chem.* **276**:47759–47762.
 70. Wertz, I. E., K. M. O'Rourke, Z. Zhang, D. Dornan, D. Arnott, R. J. Deshaies, and V. M. Dixit. 2004. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. *Science* **303**:1371–1374.
 71. Wohlschlegel, J. A., B. T. Dwyer, S. K. Dhar, C. Cvetcic, J. C. Walter, and A. Dutta. 2000. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. *Science* **290**:2309–2312.
 72. Zhao, H., and H. Piwnicka-Worms. 2001. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. *Mol. Cell. Biol.* **21**:4129–4139.
 73. Zhong, W., H. Feng, F. E. Santiago, and E. T. Kipreos. 2003. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. *Nature* **423**:885–889.
 74. Zhu, W., Y. Chen, and A. Dutta. 2004. Rereplication by depletion of geminin is seen regardless of p53 status and activates a G₂/M checkpoint. *Mol. Cell. Biol.* **24**:7140–7150.